The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: A meta-analysis

Clinical Cardiology

Volumn 35, Issue 10, 2012, Pages 598-604

  Wang, Ping ^a   Zhou, Shijie ^a   Zhou, Rui ^a,b   Liu, Gan ^c   Tang, Ping ^a   He, Jing ^a   Ma, Cong ^a   He, Yi ^a   Yang, Jinliang ^a  

^a SICHUAN UNIVERSITY   (China)

^b SOUTHWEST MEDICAL UNIVERSITY   (China)

^c CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; PLACEBO; TICLOPIDINE;

BLEEDING; BLOOD VESSEL DIAMETER; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; CONFIDENCE INTERVALS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG THERAPY, COMBINATION; HUMANS; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; TETRAZOLES; TICLOPIDINE;

EID: 84867230858     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22001     Document Type: Review

References (34)

1. Brush JE Jr, Thompson S, Ciuffo AA, et al. Retrospective comparison of a strategy of primary coronary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction in a community hospital without cardiac surgical backup. J Invasive Cardiol. 1996; 8: 91-98.
2. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA. 1997; 278: 2093-2098.
3. Fischman DL, Leon MB, Baim DS, et al. Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994; 331: 496-501.
4. Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002; 40: 2082-2089.
5. Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA. 2005; 294: 819-825.
6. Resnic FS, Wainstein M, Lee MK, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J. 2003; 145: 42-46.
7. Weintraub WS., The pathophysiology and burden of restenosis. Am J Cardiol. 2007; 100: 3K-9K.
8. Pan X, Arauz E, Krzanowski JJ, et al. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol. 1994; 48: 827-835.
9. Kubota Y, Kichikawa K, Uchida H, et al. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries: an experimental study. Invest Radiol. 1995; 30: 532-537.
10. Kunishima T, Musha H, Eto F, et al. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Ther. 1997; 19: 1058-1066.
11. Park SW, Lee CW, Kim HS, et al. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol. 2000; 86: 499-503.
12. Kamishirado H, Inoue T, Mizoguchi K, et al. Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. Am Heart J. 2002; 144: 303-308.
13. Leon MB, Baim DS, Popma JJ, et al. Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing 3 antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998; 339: 1665-1671.
14. Lee YS, Bae HJ, Kang DW, et al. Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. Cerebrovasc Dis. 2011; 32: 65-71.
15. Ahn CM, Hong SJ, Park JH, et al. Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. Heart Vessels. 2011; 26: 502-510.
16. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Hoboken, NJ: Wiley-Blackwell; 2008:xxi, 649. doi: 10.1002/9780470712184.
17. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557-560.
18. Chen YD, Lu YL, Jin ZN, et al. A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. Chin Med J. 2006; 119: 360-366.
19. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005; 112: 2826-2832.
20. Min PK, Jung JH, Ko YG, et al. Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantitative coronary angiography and volumetric intravascular ultrasound study. Circ J. 2007; 71: 1685-1690.
21. Lee SW, Park SW, Kim YH, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol. 2007; 100: 1103-1108.
22. Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus: the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol. 2008; 51: 1181-1187.
23. Lee SW, Park SW, Kim YH, et al. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. J Am Coll Cardiol. 2011; 57: 1264-1270.
24. Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J. 2009; 157: 733-739.
25. Savi P, Zachayus JL, Delesque-Touchard N, et al. The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A. 2006; 103: 11069-11074.
26. Shinoda-Tagawa T, Yamasaki Y, Yoshida S, et al. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with type II diabetes. Diabetologia. 2002; 45: 188-194.
27. Morishita R., A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis. Atheroscler Suppl. 2005; 6: 41-46.
28. Inoue T, Uchida T, Sakuma M, et al. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol. 2004; 44: 1408-1414.
29. Sumpio BE, Aruny J., Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. Perspect Vasc Surg Endovasc Ther. 2005; 17: 265-267.
30. Hiatt WR, Money SR, Brass EP., Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. 2008; 47: 330-336.
31. Takagi H, Umemoto T., Benefit, rather than safety, of cilostazol for long-term mortality in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized trials. Int J Cardiol. 2011; 153: 74-76.
32. Wenger NK., 2011 ACCF/AHA focused update of the guidelines for the management of patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 Guideline): highlights for the clinician. Clin Cardiol. 2012; 35: 3-8.
33. Algra A, van Gijn J., Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry. 1996; 60: 197-199.
34. Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ. 2000; 320: 1574-1577.